Drug
Enoblituzumab Plus Ipilimumab
Enoblituzumab Plus Ipilimumab: highest development phase Phase 1, developed by MacroGenics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| enoblituzumab plus ipilimumab NCT02381314 | Phase 1 | Melanoma |
Latest
No recent events.
Follow Enoblituzumab Plus Ipilimumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.